Previous Article | Next Article ![]()
Journal of Clinical Microbiology, July 2009, p. 2187-2193, Vol. 47, No. 7
0095-1137/09/$08.00+0 doi:10.1128/JCM.00304-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Antimicrobial Research Laboratory, SA Pathology at the Women's and Children's Hospital, North Adelaide,1 University of Adelaide, Adelaide, South Australia 5006,2 JMI Laboratories, North Liberty, Iowa 523173
Received 10 February 2009/ Returned for modification 14 April 2009/ Accepted 14 May 2009
Currently, there is no Clinical and Laboratory Standards Institute (CLSI) disk diffusion method for testing Moraxella catarrhalis susceptibility. We examined 318 clinical strains of M. catarrhalis obtained as part of the SENTRY (Asia-Pacific) Antimicrobial Surveillance Program, plus two ATCC strains. MICs were determined by the CLSI standard broth microdilution method, and zone diameters were determined on Mueller-Hinton agar incubated in 5% CO2. All strains were examined for the presence of BRO-1 and BRO-2 β-lactamases by using molecular techniques. Tentative zone diameter interpretive criteria were successfully developed for 19 antimicrobial agents, including nine β-lactams, using current MIC interpretive criteria where available or wild-type cutoff values where no prior criteria were available. The proposed interpretive criteria were highly accurate, with
0.7% very major (falsely susceptible) and
1.0% major (falsely resistant) errors, respectively.
Published ahead of print on 20 May 2009.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»